Programmable DNAzyme nanocatalysts orchestrate redox-immune coupling for time-gated cancer immunomodulation Authors: Lu Wang, Rongping Luo, Lingxiu Zou, Xiaojing Liu, Zhuojia Tang, Fengqi Dong, Zhen Wang, Jianxin Lyu, Yi Zhang Published: 2026 ABSTRACT Immune activation within tumors is governed by highly dynamic redox and mitochondrial signaling events, yet the temporal organization of these processes remains poorly defined. Here, we report a programmable DNAzyme nanocatalyst (APTZ) that enables time-dependent redox-immune coupling by translating intracellular catalytic activity into a transient biochemical signal window. The APTZ platform integrates ZnO nanoparticles, a catalase-targeting DNAzyme, and a tumor-homing aptamer, allowing acid-triggered Zn2+ release to induce sequence-specific catalytic cleavage of catalase mRNA. This reaction amplifies intracellular reactive oxygen species while depleting glutathione, leading to mitochondrial membrane depolarization, energetic collapse, and cytosolic release of mitochondrial DNA. The resulting mtDNA leakage activates the cGAS-STING pathway and induces a robust type I interferon response, thereby establishing a transient 4-6 h redox sensitization window. Leveraging this temporally confined state enhances dendritic-cell maturation and cytotoxic T-cell infiltration when immune checkpoint blockade is applied within the defined window. Conceptually, this work demonstrates that programmable DNAzyme catalysis can be harnessed to generate actionable temporal biochemical cues, providing a nanobiotechnology framework for time-guided innate immune modulation and highlighting the broader potential of DNAzyme-based nanocatalysts in dynamic cancer immunotherapy .Graphical Abstract A programmable DNAzyme nanocatalyst triggers a redox-driven cGAS-STING cascade to establish a transient 4-6 h immunogenic window. Synchronizing PD-1 blockade within this window maximizes innate and adaptive immune activation, enabling a time-synchronized immunotherapy strategy that couples catalytic redox modulation with dynamic immune regulation. Supplementary InformationThe online version contains supplementary material available at 10.1186/s12951-026-04397-z. Immune checkpoint blockade (ICB) has reshaped the therapeutic landscape of multiple malignancies, yet its clinical efficacy remains highly variable due to the profoundly immunosuppressive tumor microenvironment (TME) [1, 2]. Tumor cells maintain an abnormal redox equilibrium that suppresses immunogenic stress, dampens antigen presentation, and restricts T-cell infiltration, collectively limiting patient responsiveness to ICB [3–5]. Although a broad range of nanotherapeutic strategies has been developed to modulate tumor redox states [6], most operate in a largely static fashion and fail to address a fundamental dimension of therapeutic success, the temporal dynamics of redox-immune coupling within tumors. In clinical practice, ICB is administered empirically without regard to when tumors are most permissive to immune engagement, leading to suboptimal responses [7]. Strategies that perturb redox homeostasis while generating actionable biochemical cues to guide the timing of immunotherapy therefore represent an unmet need at the interface of nanomedicine and cancer immunology. Redox dysregulation is intimately linked to mitochondrial homeostasis, metabolic plasticity, and innate immune sensing in tumors [6, 8, 9]. Excessive antioxidant buffering, driven by enzymes such as catalase and glutathione-dependent pathways, enables cancer cells to neutralize reactive oxygen species (ROS) and escape immunogenic stress [10]. Perturbing this balance can precipitate mitochondrial dysfunction, loss of membrane potential, ATP depletion, and the cytosolic release of mitochondrial DNA (mtDNA), a potent danger-associated molecular pattern that activates the cGAS-STING pathway [11–14]. STING signaling elicits type I interferon production, enhances dendritic-cell maturation, and promotes cytotoxic T-cell recruitment, serving as a critical bridge between intracellular metabolic stress and antitumor immunity [15–17]. However, how to deliberately trigger and temporally control this redox-mitochondria-innate immunity axis remains poorly defined, limiting efforts to translate redox-mediated immunogenicity into time-sensitive therapeutic strategies. Programmable DNAzymes have emerged as versatile catalytic nucleic acids capable of sequence-specific mRNA cleavage and stimulus-responsive activation [18]. Advances in DNAzyme engineering, spanning metal ion-dependent catalysis, aptamer-guided targeting, and nanomaterial-assisted delivery, have enabled their use in gene regulation, redox modulation, and immunometabolic reprogramming [19–21]. However, existing DNAzyme-based nanoplatforms typically function as static catalytic systems, designed to silence a target gene or amplify ROS without generating the dynamic biochemical cues necessary to guide immunotherapy timing [22–24]. Although DNAzyme-driven redox perturbation can initiate innate immune signaling, current platforms do not integrate these processes into a temporally ordered cascade that defines a discrete window of heightened immunotherapeutic responsiveness. To address these limitations, we developed a programmable DNAzyme nanocatalyst (APTZ) that establishes a intrinsically defined redox sensitization window to guide time-gated cancer immunotherapy (Fig. 1). The APTZ platform integrates pH-responsive ZnO nanoparticles with a catalase-targeting DNAzyme and a tumor-homing aptamer, enabling Zn2+-activated catalytic cleavage of catalase mRNA. This catalytic event synchronizes ROS amplification with glutathione depletion, driving mitochondrial collapse and cytosolic mtDNA leakage. The released mtDNA robustly activates cGAS-STING signaling, producing type I interferons that intrinsically mark a 4-6 h window of heightened tumor immunogenicity. Administering PD-1 blockade within this window significantly enhances dendritic-cell maturation, cytotoxic T-cell infiltration, and tumor regression, while minimizing systemic toxicity. Conceptually, this work introduces a redox-immune coupling strategy in which intracellular catalytic events are translated into temporal biochemical signatures that guide when immune interventions should occur. Beyond the specific APTZ design, our findings reveal a broader mechanistic principle: catalytic mRNA cleavage can be programmed to generate actionable temporal cues for precision immunotherapy. This framework establishes a foundation for developing bioactive materials that exploit tumor spatiotemporal biology and provides a generalizable strategy for enhancing ICB efficacy through time-optimized immune activation. Fig. 1Schematic illustration of the APTZ nanoplatform for temporally guided redox-sensitized cancer immunotherapy. APTZ is assembled via one-pot integration of ZnO nanoparticles, a catalase-targeting DNAzyme, and the AS1411 aptamer, enabling tumor-selective delivery and intracellular activation. Upon cellular uptake and lysosomal escape, acidic conditions trigger Zn2+ release, activating DNAzyme-mediated catalase mRNA cleavage, leading to reactive oxygen species (ROS) amplification and glutathione (GSH) depletion. The temporal convergence of these redox perturbations establishes a transient redox sensitization window associated mitochondrial stress. Mitochondrial dysfunction is characterized by ΔΨm collapse, ATP depletion, and cytosolic mtDNA leakage, thereby promoting innate immune signaling. This responsesynergizes with αPD-1 therapy to enhance dendritic cell maturation and CD8+ T cell infiltration. Overall, APTZ enables time-directed amplification of antitumor immune responses through coordinated redox and immune modulation. Schematic illustration of the APTZ nanoplatform for temporally guided redox-sensitized cancer immunotherapy. APTZ is assembled via one-pot integration of ZnO nanoparticles, a catalase-targeting DNAzyme, and the AS1411 aptamer, enabling tumor-selective delivery and intracellular activation. Upon cellular uptake and lysosomal escape, acidic conditions trigger Zn2+ release, activating DNAzyme-mediated catalase mRNA cleavage, leading to reactive oxygen species (ROS) amplification and glutathione (GSH) depletion. The temporal convergence of these redox perturbations establishes a transient redox sensitization window associated mitochondrial stress. Mitochondrial dysfunction is characterized by ΔΨm collapse, ATP depletion, and cytosolic mtDNA leakage, thereby promoting innate immune signaling. This responsesynergizes with αPD-1 therapy to enhance dendritic cell maturation and CD8+ T cell infiltration. Overall, APTZ enables time-directed amplification of antitumor immune responses through coordinated redox and immune modulation. Results and discussion Design, synthesis, and characterization of APTZ nanoplatform The APTZ nanoplatform was rationally designed to integrate pH-responsive ZnO nanoparticles [25] with DNA nanostructures comprising catalytic DNAzyme strands and the tumor-targeting AS1411 aptamer (Fig. 2a) [26]. All oligonucleotide sequences, including DNAzyme-1, DNAzyme-2, AS1411, the linker strand, and corresponding control variants, are detailed in Supplementary Table S1. To evaluate the structural stability and hybridization efficiency of the DNA construct, NUPACK simulations were performed under physiological conditions (37 °C) [27, 28]. The complete assembly comprising DNAzyme-1, DNAzyme-2, AS1411 aptamer, and the linker exhibited the thermodynamically most stable configuration, with a minimum free energy (MFE) of -77.28 kcal mol−1. Progressive exclusion of individual components resulted in less favorable structures, consistent with diminished base-pairing interactions and reduced folding complexity (Figure S1), thereby supporting the modular design of the APTZ. Hybridization optimization further revealed that a DNAzyme-to-aptamer ratio of 1:5 yielded the most stable and well-defined assembly (Figure S2), While stepwise polyacrylamide gel electrophoresis (PAGE) verified the successful formation of the multicomponent DNA architecture (Figure S3). Transmission electron microscopy (TEM) images revealed that ZnO nanoparticles retained uniform morphology after DNA conjugation, resulting in APTZ particles with a slightly thickened DNA corona (Fig. 2b). Dynamic light scattering (DLS) analysis revealed an increase in hydrodynamic diameter from ~90 nm (ZnO) to ~105 nm (APTZ) (Fig. 2d), indicative of successful DNA surface functionalization. Correspondingly, the zeta potential shifted from +9.8 mV to -11.2 mV after assembly (Fig. 2c), reflecting the negative charge of the DNA shell. High-angle annular dark-field scanning transmission eletron microscopy (HAADF-STEM) image showed a homogeneous distribution of Zn, C, N, O, and P within APTZ (Fig. 2e), while X-ray photoelectron spectroscopy (XPS) confirmed the coexistence of ZnO and nucleic acid components (Fig. 2f). Atomic force microscopy (AFM) provided additional support for successful surface modification. Compared with bare ZnO nanoparticles, wwhich displayed smooth surfaces and an average height of approximately 7.6 nm, APTZ exhibited a more complex surface topography and an increased height of approximately 16.3 nm, consistent with DNA coating(Figure S4). The acid-responsive Zn2+ release profile of APTZ was next evaluated using inductively coupled plasma mass spectrometry (ICP-MS). At neutral pH (7.4), minimal Zn2+ release was observed, whereas acidic conditions (pH 5.5) triggered rapid and substantial ion release, mimicking the endolysosomal tumor microenvironment (Fig. 2h). TEM imaging validated these findings, showing progressive disintegration of APTZ structures under acidic conditions (Fig. 2g). To further assess colloidal and structural stability in biologically relevant media, APTZ was incubated in either complete cell culture medium (CCM) or PBS at 37 °C for up to 12 h. Native PAGE analysis showed no detectable degradation during this stage, indicating excellent colloidal and nuclease stability in biological environments (Figure S5). Functional validation of the DNAzyme module was then validated using an mRNA substrate together with a catalytically inactive mutant DNAzyme (muDNAzyme) as a control. The active DNAzyme exhibited clear Zn2+-dependent substrate cleavage, whereas muDNAzyme showed inactivite across identical Zn2+ concentrations, confirming sequence-specific catalytic activity (Supplementary Figure S6). Importantly, PAGE cleavage assays demonstrated that Zn2+ released from APTZ at pH 5.5 was sufficient to activate DNAzyme-mediated cleavage, while no significant cleavage occurred at pH 7.4 (Fig. 2i). Together, these results confirm the successful construction of a modular, pH-responsive APTZ nanoplatform with well-defined structural characteristics, robust physiological stability, tumor-relevant Zn2+ release, and programmable catalytic function, thereby providing a solid basis for subsequent evaluation of its therapeutic potential. Cellular uptake, lysosomal escape, and intracellular Zn2+ release Efficient cellular uptake and timely lysosomal escape are essential prerequisites for the success of nanoparticle-based gene regulation platforms [29, 30]. To assess these processes, confocal laser scanning microscopy (CLSM) was performed in 4T1 cells using Cy5-labeled APTZ. Compared with the control construct PTZ, which consists of DNAzyme-functionalized ZnO nanoparticles lacking the AS1411 aptamer, APTZ exhibited significantly higher intracellular fluorescence after 6 h of incubation (Fig. 3a). Quantitative analysis revealed a ~3.4-fold increase in uptake efficiency for APTZ relative to PTZ (Fig. 3b), underscoring the contribution of AS1411-mediated nucleolin targeting to cellular internalization. Time-course imaging further showed a progressive increase in intracellular fluorescence from 1 to 6 h, which plateaued thereafter, indicating both rapid and sustained uptake kinetics (Figure S7). Fig. 2Design, physicochemical characterization, and pH-responsive behavior of the APTZ nanoplatform. (a) Schematic illustration of APTZ assembly and acid-triggered Zn2+ release for DNAzyme activation. (b) TEM images of ZnO and APTZ nanoparticles; insets show corresponding schematic structures. (c) Zeta potential and (d) hydrodynamic size distribution of ZnO and APTZ. (e) HAADF-STEM image and corresponding elemental mappings of O, Zn, and P. (f) XPS survey spectrum of APTZ. (g) TEM image of APTZ after incubation at pH 5.5. Inset shows the schematicillustration of pH-responsive disassembly. (h) Zn2+ release profiles of APTZ at pH 5.5 and 7.4. (i) PAGE analysis of DNAzyme substrate cleavage at varying APTZ concentrations and pH conditions. Design, physicochemical characterization, and pH-responsive behavior of the APTZ nanoplatform. (a) Schematic illustration of APTZ assembly and acid-triggered Zn2+ release for DNAzyme activation. (b) TEM images of ZnO and APTZ nanoparticles; insets show corresponding schematic structures. (c) Zeta potential and (d) hydrodynamic size distribution of ZnO and APTZ. (e) HAADF-STEM image and corresponding elemental mappings of O, Zn, and P. (f) XPS survey spectrum of APTZ. (g) TEM image of APTZ after incubation at pH 5.5. Inset shows the schematicillustration of pH-responsive disassembly. (h) Zn2+ release profiles of APTZ at pH 5.5 and 7.4. (i) PAGE analysis of DNAzyme substrate cleavage at varying APTZ concentrations and pH conditions. Following internalization, the intracellular trafficking of APTZ was tracked using LysoTracker staining to evaluate lysosomal engagement and escape. Pearson’s correlation coefficient (PCC) was calculated to quantify colocalization [31] between Cy5-APTZ and lysosomes (Fig. 3c-d). At 1 h, PCC values were low (~0.17), indicating minimal lysosomal association. Colocalization gradually increased to ~0.33 at 2 h andreached a peak of ~0.68 at 4 h, consistent with maximal lysosomal localization. By 6 h, PCC values declined to ~0.24, indicating substantial endosomal escape. These observations were corroborated by CLSM images showing time-dependent colocalization of APTZ with lysosomes, followed by partial dissociation after 4-6 h (Figure S8), supporting efficient escape from the endo-lysosomal system. This temporal profile is consistent with the expected behavior of ZnO-based nanocarriers engineered for acid-triggered cargo release. To further assess the functional consequence of lysosomal escape, intracellular Zn2+ levels were measured using ICP-MS [32]. APTZ treatment induced a time-dependent increase in cytosolic Zn2+ concentration, rising from ~ 0.3 pg cell−1 at baseline to ~0.9 pg cell−1 at 4 h, and exceeding 1.1 pg cell−1 by 8-12 h (Fig. 3e). This Zn2+ release profile aligns temporally with lysosomal disassembly and supports the pH-responsive degradation of ZnO core under acidic conditions. Fig. 3Cellular uptake, endo-lysosomal trafficking, and cytotoxicity of APTZ. (a) CLSM images of 4T1 cells after 4 h incubation with PTZ or Cy5-labeled APTZ. Nuclei stained with DAPI (blue); Cy5 signals in red. (b) Quantification of intracellular Cy5 mean fluorescence intensity (MFI). (c) Time-resolved colocalization of APTZ (red) with lysosomes (green) from 1 to 6 h; representative line-scan profiles illustrate fluorescence overlap. (d) Pearson's correaltion coefficient (PCC) analysis quantifying APTZ-lysosome colocalization over time. (e) Intracellular Zn content measured by ICP-MS at indicated time points. (f) Cell viability of 4T1 cells after 24 h treatment with ZnO, PTZ, or APTZ at varying concentrations. Quantitative data are based on n= 3 independent biological replicates. Statistical significance was determined by one- or two-way ANOVA with Tukey’s post hoc test: *p < 0.05, ** p < 0.01, **** p < 0.0001. Cellular uptake, endo-lysosomal trafficking, and cytotoxicity of APTZ. (a) CLSM images of 4T1 cells after 4 h incubation with PTZ or Cy5-labeled APTZ. Nuclei stained with DAPI (blue); Cy5 signals in red. (b) Quantification of intracellular Cy5 mean fluorescence intensity (MFI). (c) Time-resolved colocalization of APTZ (red) with lysosomes (green) from 1 to 6 h; representative line-scan profiles illustrate fluorescence overlap. (d) Pearson's correaltion coefficient (PCC) analysis quantifying APTZ-lysosome colocalization over time. (e) Intracellular Zn content measured by ICP-MS at indicated time points. (f) Cell viability of 4T1 cells after 24 h treatment with ZnO, PTZ, or APTZ at varying concentrations. Quantitative data are based on n= 3 independent biological replicates. Statistical significance was determined by one- or two-way ANOVA with Tukey’s post hoc test: *p < 0.05, ** p < 0.01, **** p < 0.0001. The biological relevance of these processes was further demonstrated through cytotoxicity assays. APTZ induced significant dose-dependent inhibition of 4T1 cell viability, outperforming both PTZ and unmodified ZnO nanoparticles (Fig. 3f). This enhanced cytotoxicity reflects the synergistic effect of tumor-selective Zn2+ release and catalytic DNAzyme activity. Taken together, these findings establish that APTZ achieves efficient aptamer-mediated cellular uptake, timely lysosomal escape, and robust intracellular Zn2+ release, thereby generating a favorable intracellular environment for downstream DNAzyme-mediated gene regulation and therapeutic action. APTZ induces redox imbalance and establishes a transient sensitization window To investigate whether APTZ modulates intracellular redox homeostasis, we first examined the expression of catalase, a key antioxidant enzyme [33]. Western blot analysis showed that catalase expression was markedly reduced to ~55% of baseline following APTZ treatment, significantly lower than that observed in ZnO (~93%) or APT-treated cells (~87%) (Fig. 4a). This downregulation was largely abolished in cells treated with mutant APTZ (mAPTZ; ~90%) and restored upon Zn2+ chelation with TPEN (~88%), indicating that both Zn2+ release and DNAzyme activity are essential for catalase suppression. Taken together, these results support a DNAzyme-mediated mRNA cleavage mechanism as the primary driver of catalase downregulation, with Zn2+ release serving as an essential cofactor for catalytic activation. While downstream Zn2+- or ROS-associated regulatory effects may further modulate cellular redox homeostasis, the present analysis focuses on the DNAzyme-dominated mechanism underlying catalase suppression. Consistent with impaired antioxidant capacity resulting from catalase depletion, intracellular reactive oxygen species (ROS) levels were subsequently assessed using DCFH-DA staining. Confocal imaging revealed intense green fluorescence in APTZ-treated cells, corresponding to a ~1.8-fold increase in ROS relavtive to untreated controls (Fig. 4b,c). In contrast, ROS levels remained near baseline (~1.1-fold) in cells treated with APT, mAPTZ, or APTZ + TPEN, further confirming the catalytic, Zn2+-dependent nature of ROS generation. Dose-dependent studies demonstrated that APTZ elevated ROS to ~2.1-fold at 400 µM and ~2.3-fold at 600 µM (Fig. 4d, left). Concurrently, intracellular glutathione (GSH) levels were monitored to evaluate antioxidant depletion. APTZ treatment caused rapid, concentration- and time-dependent GSH consumption. At 400 µM, GSH dropped to ~65% at 4 h and ~47% at 6 h, indicating substantial depletion of the cellular redox buffer (Fig. 4d, right). When ROS and GSH dynamics were analyzed in tandem, a distinct redox sensitization window was identified between 4 and 6 h post-treatment, characterized by a ROS peak (~200% of baseline) and GSH depletion exceeding 50% (Fig. 4e). Collectively, the 4-6 h interval is defined here as a redox sensitization window not by a single readout, but by the temporal convergence of multiple stress-associated indicators, including peak ROS accumulation, pronounced GSH depletion, and associated mitochondrial stress. This window therefore represents an integrated cellular state characterized by maximal redox imbalance and heightened vulnerability to downstream stress responses. From a functional perspective, this temporal window likely represents a period of heightened susceptibility to oxidative stress-mediated apoptosis. Indeed, flow cytometry revealed a time-dependent increase in apoptotic cells, rising from ~5% at baseline to ~14% at 2 h, ~23% at 4 h, and ~25% at 8 h following APTZ exposure (Fig. 4f). Quantitative analysis showed that early apoptosis peaked at 4 h, while late apoptosis continued to increase, reaching a maximum at 8 h. The combined apoptotic burden was highest at 6 h, aligning closely with peak Zn2+ release and oxidative imbalance (Figure S9). Live/dead staining using Calcein-AM/PI further confirmed this progression, with increased PI uptake over time indicative of progressive membrane disruption (Figure S10). To confirm the mechanistic role of oxidative stress, antioxidant rescue experiments were performed using N-acetylcysteine (NAC) [34–36]. NAC pretreatment reduced ROS accumulation by ~60% and improved cell viability by ~50% compared to APTZ treatment alone, substantiating the contribution of ROS to APTZ-induced cytotoxicity (Figure S11). Together, these findings demonstrate that APTZ induces a coordinated redox imbalance through catalase knockdown, ROS amplification, and GSH depletion. This establishes a transient but well-defined redox sensitization window during which tumor cells become particularly vulnerable to apoptosis, thereby providinga critical mechanistic foundation for subsequent therapeutic interventions. Redox-mitochondria crosstalk triggers cGAS-STING signaling Mitochondria are central regulators of both cellular redox homeostasis and innate immune activation [15, 37]. We therefore investigated whether APTZ-induced redox stress perturbs mitochondrial integrity and engages cytosolic DNA sensing pathways. As shown in Fig. 5a-d, APTZ triggered progressive mitochondrial degeneration characterized by structural collapse and metabolic failure. TEM revealed time-dependent rarefaction of cristae architecture. As the primary site of oxidative phosphorylation, cristae harbor key respiratory complexes; accordingly, their structural loss compromises electron transport efficiency, reduces ATP synthesis, and reflects impaired mitochondrial bioenergetics [38, 39]. Quantitative scoring showed a decline from well-defined cristae (~30-40% area; score 1) at baseline to near-complete cristae loss (<10% area; score 4) by 6 h post-treatment, followed by partial recovery at 8 h (score 2-3). These ultrastructural disruptions coincided with pronounced mitochondrial depolarization. The JC-1 red/green fluorescence ratio, a surrogate for membrane potential (ΔΨm) [40], declined from ~2.6 at baseline to ~0.6 at 6 h, representing an approximately4.3-fold reduction, with a modest rebound at 8 h (~0.9), indicating partial repolarization (Fig. 5c). This structural collapse was paralleled by marked functional decline. Intracellular ATP levels decreased to ~70% of control at 4 h and further to ~45% at 6 h, remaining suppressed thereafter (~50%) (Fig. 5e). Oxygen consumption rate (OCR) assays confirmed a global impairment of mitochondrial respiration, including reduced basal respiration, maximal respiratory capacity, and spare respiratory capacity [41, 42], further substantiating widespread energetic collapse (Fig. 5f). Collectively, these data demonstrate that APTZ induces temporally coordianted mitochondrial structural disruption and metabolic dysfunction. Importantly, this mitochondrial crisis emerged within the previously defined redox sensitization window and was accompanied by the cytosolic release of mitochondrial DNA (mtDNA), as determined by qPCR analysis of cytosolic fractions (Fig. 5h). The spatiotemporal pattern of mtDNA leakage closely mirrored the redox and mitochondrial damage dynamics, peaking at 4-6 h. In this context, mtDNA leakage is regarded as an upstream initiating signal for cGAS activation rather than a coincident byproduct of mitochondrial stress. This release event served as a trigger for innate immune sensing via the cGAS-STING pathway [16, 43]. Enzyme-linked immunosorbent assays (ELISAs) showed a time-dependent increase in intracellular cyclic GMP-AMP (cGAMP), the second messenger generated by activated cGAS (Figure S12) [44], alongside elevated IFN-β secretion (Figure S13). Western blot analysis further confirmed phosphorylation of core signaling components STING, TBK1, and IRF3, culminating in activation of type I interferon responses (Fig. 5i-j). Fig. 4APTZ disrupts intracellular redox homeostasis and establishes a redox sensitization window. (a) Western blot analysis of catalase expression in 4T1 cells following treatment with ZnO, APT, APTZ, APTZ+TPEN, or mAPTZ. β-actin serves as a loading control, and densitometric quantification is shown below. (b) CLSM images of ROS generation in 4T1 cells after 4 h incubation with the indicated formulations, using DCFH-DA (green) for ROS and DAPI (blue) for nuclei. Scale bar: 50 μm. (c) Quantification of intracellular ROS fluorescence intensity. (d) Time- and dose-dependent profiles of intracellular ROS (left) and GSH (right) levels after APTZ treatment, normalized to control. (e) Overlay analysis of ROS accumulation and GSH depletion identifying a redox sensitization window between 4 and 6 h. (f) Flow cytometric analysis of Annexin V-FITC/PI-stained 4T1 cells at indicated time points following APTZ treatment. Quantitative data are based on n = 3 independent biological replicates. Statistical significance was determined using one-way ANOVA with Tukey’s post hoc test: **p < 0.01, *** p < 0.001, **** p < 0.0001. APTZ disrupts intracellular redox homeostasis and establishes a redox sensitization window. (a) Western blot analysis of catalase expression in 4T1 cells following treatment with ZnO, APT, APTZ, APTZ+TPEN, or mAPTZ. β-actin serves as a loading control, and densitometric quantification is shown below. (b) CLSM images of ROS generation in 4T1 cells after 4 h incubation with the indicated formulations, using DCFH-DA (green) for ROS and DAPI (blue) for nuclei. Scale bar: 50 μm. (c) Quantification of intracellular ROS fluorescence intensity. (d) Time- and dose-dependent profiles of intracellular ROS (left) and GSH (right) levels after APTZ treatment, normalized to control. (e) Overlay analysis of ROS accumulation and GSH depletion identifying a redox sensitization window between 4 and 6 h. (f) Flow cytometric analysis of Annexin V-FITC/PI-stained 4T1 cells at indicated time points following APTZ treatment. Quantitative data are based on n = 3 independent biological replicates. Statistical significance was determined using one-way ANOVA with Tukey’s post hoc test: **p < 0.01, *** p < 0.001, **** p < 0.0001. Together, these results establish that APTZ-induced redox imbalance initiates a feedforward cascade of mitochondrial damage, mtDNA cytosolic leakage, and innate immune activation via cGAS-STING signaling. This redox-mitochondria-immunity axis provides a mechanistic foundation linking intracellular metabolic stress to immunostimulatory outcomes, reinforcing the therapeutic potential of APTZ as a redox-guided immune modulator. In vivo antitumor efficacy and biosafety Having established that APTZ induces redox imbalance, mitochondrial dysfunction, and activation of the cGAS-STING axis in vitro, we next explored whether these effects could be translated into therapeutic benefit by temporally aligning immune checkpoint blockade with the intracellular redox sensitization window. To this end, a 4T1 orthotopic breast tumor model was employed, and mice were assigned to six treatment groups: saline, αPD-1, APTZ, APTZ(0.5 h)+αPD-1, APTZ(5 h)+αPD-1, and APTZ(8 h)+αPD-1 (Fig. 6a). αPD-1 was administered at the indicated fixed time points (0.5 h, 5 h, or 8 h) following APTZ injection, with APTZ administration defined as time zero. This design enabled evaluation of the therapeutic impact of checkpoint blockade synchronized with APTZ-triggered redox dynamics. In vivo ROS imaging confirmed that APTZ elicited a rapid oxidative burst within the TME, peaking at 4-6 h post-administration and returning toward baseline by 8 h (Fig. 6c). This profile closely mirrored the redox window identified in cellular models, characterized by elevated ROS and GSH depletion. Notably, therapeutic synergy between APTZ and αPD-1 was highly dependent on temporal coordination. When αPD-1 was administered at the 5 h, coinciding with peak redox sensitization, the combination regimen achieved the most pronounced tumor growth inhibition (TGI ≈ 78%), representing a 1.8-fold improvement over APTZ monotherapy (TGI ≈ 43%) and a 2.8-fold enhancement relative to αPD-1 alone (TGI ≈ 28%) (Fig. 6b, e). Conversely, checkpoint blockade outside the defined window, at either 0.5h or 8 hafter APTZ injection, led to suboptimal tumor suppression (TGI ≈ 56% and 49%, respectively). These findings emphasize that temporal synchronization with the APTZ-induced redox window is critical to unlock maximal immunotherapeutic potential. Ex vivo tumor imaging further supported this conclusion, showing markedly reduced tumor burdens in the APTZ(5 h)+αPD-1 group (Supplementary Figure S14). Histological analyses confirmed these outcomes. H&E staining revealed extensive necrotic regions, and TUNEL assays showed robust apoptotic cell death in tumors harvested at the optimal treatment interval (Fig. 6f). Fig. 5APTZ induces mitochondrial dysfunction and activates the cGAS-STING innate immune pathway. (a) JC-1 staining of 4T1 cells treated with APTZ at different time points (0-8 h). Scale bar: 50 μm. (b) TEM images illustrating progressive mitochondrial damage and cristae rarefaction post-APTZ treatment. Yellow circles denote disrupted cristae. Scale bar: 500 nm. (c) Quantification of JC-1 red/green fluorescence ratio. (d) Semi-quantitative scoring of mitochondrial cristae density (n = 20 mitochondria per group). (e) Intracellular ATP levels at indicated time points, normalized to baseline. (f) Mitochondrial oxygen consumption rate (OCR) analysis of time-dependent changes in basal respiration (Basal), proton leak-associated respiration (Proton Leak), maximal respiration (Max Resp), spare respiratory capacity (Spare Resp), and coupling efficiency (Coupling Eff.) following APTZ treatment over time. (g) Schematic of APTZ-triggered mitochondrial disruption, mtDNA leakage, and downstream cGAS-STING activation. (h) Quantification of cytosolic mtDNA release via qPCR. (i) Western blot analysis of phosphorylated and total STING, TBK1, and IRF3 levels following APTZ treatment. (j) Densitometric quantification of phosphorylation ratios. Quantitative data are based on n = 3 independent biological replicates. Statistical significance was determined using one-way ANOVA with Tukey’s post hoc test: **p < 0.01, ***p < 0.001, ****p < 0.0001. APTZ induces mitochondrial dysfunction and activates the cGAS-STING innate immune pathway. (a) JC-1 staining of 4T1 cells treated with APTZ at different time points (0-8 h). Scale bar: 50 μm. (b) TEM images illustrating progressive mitochondrial damage and cristae rarefaction post-APTZ treatment. Yellow circles denote disrupted cristae. Scale bar: 500 nm. (c) Quantification of JC-1 red/green fluorescence ratio. (d) Semi-quantitative scoring of mitochondrial cristae density (n = 20 mitochondria per group). (e) Intracellular ATP levels at indicated time points, normalized to baseline. (f) Mitochondrial oxygen consumption rate (OCR) analysis of time-dependent changes in basal respiration (Basal), proton leak-associated respiration (Proton Leak), maximal respiration (Max Resp), spare respiratory capacity (Spare Resp), and coupling efficiency (Coupling Eff.) following APTZ treatment over time. (g) Schematic of APTZ-triggered mitochondrial disruption, mtDNA leakage, and downstream cGAS-STING activation. (h) Quantification of cytosolic mtDNA release via qPCR. (i) Western blot analysis of phosphorylated and total STING, TBK1, and IRF3 levels following APTZ treatment. (j) Densitometric quantification of phosphorylation ratios. Quantitative data are based on n = 3 independent biological replicates. Statistical significance was determined using one-way ANOVA with Tukey’s post hoc test: **p < 0.01, ***p < 0.001, ****p < 0.0001. Importantly, the potent therapeutic efficacy of this time-coordinated regimen did not come at the cost of systemic toxicity. Body weights remained stable across all groups (Fig. 5d), and key serum biochemical parameters (ALT, AST, LDH, CREA, UREA) remained within normal limits (Supplementary Figure S15). H&E staining of major organs, including heart, liver, spleen, lung, and kidney, showed no evidence of inflammation, necrosis, or histopathological abnormalities (Supplementary Figure S16), supporting the biosafety of APTZ-based interventions. In summary, these results demonstrate that APTZ not only exerts intrinsic antitumor effects but also transiently reprograms the tumor redox landscape to render malignant cells more responsive to immune checkpoint blockade. By aligning αPD-1 administration with this redox-defined window, the APTZ platform achieves enhanced therapeutic efficacy while preserving systemic safety, establishing a mechanistically grounded paradigm for time-sensitive redox-immune combination strategies. Fig. 6In vivo antitumor efficacy and biosafety of time-synchronized APTZ and αPD-1combination therapy. (a) Schematic illustration of the treatment schedule in 4T1 tumor-bearing mice, showing APTZ administration followed by αPD-1 delivery at defined intervals aligned with the redox sensitization window. (b) Tumor growth inhibition (TGI) ratios across treatment groups on day 14. (c) In vivo ROS imaging of tumors at 0-8 h post-APTZ injection. (d) Body weight monitoring throughout the study, indicating minimal systemic toxicity. (e) Tumor growth curves and corresponding individual tumor volume trajectories for each treatment group. (f) Representative H&E and TUNEL staining of tumor sections. Scale bar: 100 μm. Quantitative data are based on n = 5 mice per group. Statistical significance was determined using one-way ANOVA with Tukey’s post hoc test: ****p < 0.0001. In vivo antitumor efficacy and biosafety of time-synchronized APTZ and αPD-1combination therapy. (a) Schematic illustration of the treatment schedule in 4T1 tumor-bearing mice, showing APTZ administration followed by αPD-1 delivery at defined intervals aligned with the redox sensitization window. (b) Tumor growth inhibition (TGI) ratios across treatment groups on day 14. (c) In vivo ROS imaging of tumors at 0-8 h post-APTZ injection. (d) Body weight monitoring throughout the study, indicating minimal systemic toxicity. (e) Tumor growth curves and corresponding individual tumor volume trajectories for each treatment group. (f) Representative H&E and TUNEL staining of tumor sections. Scale bar: 100 μm. Quantitative data are based on n = 5 mice per group. Statistical significance was determined using one-way ANOVA with Tukey’s post hoc test: ****p < 0.0001. In vivo immune response Having established the therapeutic efficacy and biosafety of APTZ, we next interrogated whether its antitumor activity was associated with coordinated activation of innate and adaptive immune responses. It should be noted that the primary contribution of the AS1411 aptamer in this platform is to enhance tumor-targeted cellular uptake and delivery efficiency, as demonstrated by the comparison between PTZ and APTZ. In contrast, the observed redox disruption and subsequent immune activation in vivo are predominantly governed by the DNAzyme-ZnO core, which drives the redox-mitochondria-cGAS-STING signaling cascade. Building on our earlier demonstration that APTZ establishes a transient intracellular redox sensitization window, we hypothesized that this temporal state could serve as a critical determinant of immunopotentiation, particularly when leveraged to synchronize immune checkpoint therapy. Western blot analysis of tumor lysates revealed pronounced activation of the cGAS-STING innate immune pathway in response to temporally optimized combination treatment. Compared to αPD-1 monotherapy, the APTZ(5 h)+αPD-1 group exhibited marked upregulation of phosphorylated STING, TBK1, and IRF3, with approximately1.9-, 2.1-, and 2.0-fold increases, respectively, indicative of robust cytosolic DNA sensing and downstream inflammatory signaling (Fig. 7a,b). This activation was accompanied by significant downregulation of catalase (0.6-fold relative to baseline), consistent with redox disruption acting upstream of STING pathway engagement (Fig. 7c). Functionally, this molecular reprogramming resulted in a proinflammatory TME conducive to immune activation. Levels of interferon-β (IFN-β) and the chemokine CXCL10 were elevated by ~3.5- and 4.1-fold, respectively, in the APTZ(5 h)+αPD-1 group relative to saline controls (Fig. 7d,e), thereby creating a cytokine milieu that facilitated dendritic cell (DC) activation and effector T cell recruitment. Flow cytometric profiling confirmed significant maturation of DCs across both local and systemic immune compartments. In tumor-draining lymph nodes (dLNs), mature CD80+CD86+ DCs expanded from ~6.1% in saline-treated mice to 17.8% with APTZ monotherapy and further surged to 40.5% with the APTZ(5 h)+αPD-1 regimen (Fig. 7f, h). Intratumoral DC maturation mirrored this trend, reaching ~31.9% in the optimized group (Fig. 7i). Importantly, splenic DC maturation also increased to ~11.6%, indicating systemic immune activation beyond the primary tumor site (Figure S17). These innate immune changes were accompanied by pronounced remodeling of the adaptive T cell landscape. APTZ alone increased intratumoral CD8+ cytotoxic T cells from 24.8% to 61.2%, whereas temporally optimized co-treatment further elevated this population to 75.3% (Fig. 7g-j). Similar enhancements were observed in peripheral lymphoid tissues, where CD8+ T frequencies in dLNs and spleens reached 64.3% and 70.6%, respectively, under the APTZ(5 h)+αPD-1 protocol (Figure S18). Notably, this expansion was accompanied by a relative contraction of CD4+ T cells, suggesting a phenotypic shift toward cytotoxic effector responses. Taken together, these findings demonstrate that APTZ orchestrates a synergistic interplay between direct tumoricidal activity and immune modulation, thereby reprogramming the tumor immune microenvironment through redox-mediated mechanisms. By transiently perturbing intracellular redox homeostasis, APTZ activates innate DNA sensing pathways and primes the tumor for immune engagement. Critically, temporal synchronization of αPD-1 therapy with this redox sensitization window amplifies systemic dendritic cell maturation, cytokine production, and cytotoxic T cell infiltration. These synergistic effects underscore the importance of kinetic coordination in redox-immune combination therapy and establish a mechanistic rationale for the design of time-guided immunotherapeutic regimens. Fig. 7Time-gated APTZ enhances innate and adaptive immune responses in vivo. (a) Western blot analysis of phosphorylated and total STING, TBK1, and IRF3, along with catalase, in tumor lysates from six treatment groups: G1 (saline), G2 (αPD-1), G3 (APTZ), G4 (APTZ 0.5 h + αPD-1), G5 (APTZ 5 h + αPD-1), and G6 (APTZ 8 h + αPD-1). (b) Quantification of phosphorylation ratios for p-STING/STING, p-TBK1/TBK1, and p-IRF3/IRF3. (c) Relative catalase expression normalized to β-actin. (d,e) ELISA measurements of IFN-β and CXCL10 levels in tumor tissues. (f) Representative flow cytometry plots of CD80+CD86+ dendritic cell (DC) maturation in draining lymph nodes (dLNs) and tumors across treatment groups. (g) Representative flow cytometry analysis of intratumoral CD4+ and CD8+ T cell populations. (h,i) Quantification of DC maturation in dLNs and tumors, respectively . (j) Percentage of tumor-infiltrating CD8+ T cells. Quantitative data are based on n = 3 mice per group. Statistical significance was determined using one-way ANOVA with Tukey’s post hoc test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Time-gated APTZ enhances innate and adaptive immune responses in vivo. (a) Western blot analysis of phosphorylated and total STING, TBK1, and IRF3, along with catalase, in tumor lysates from six treatment groups: G1 (saline), G2 (αPD-1), G3 (APTZ), G4 (APTZ 0.5 h + αPD-1), G5 (APTZ 5 h + αPD-1), and G6 (APTZ 8 h + αPD-1). (b) Quantification of phosphorylation ratios for p-STING/STING, p-TBK1/TBK1, and p-IRF3/IRF3. (c) Relative catalase expression normalized to β-actin. (d,e) ELISA measurements of IFN-β and CXCL10 levels in tumor tissues. (f) Representative flow cytometry plots of CD80+CD86+ dendritic cell (DC) maturation in draining lymph nodes (dLNs) and tumors across treatment groups. (g) Representative flow cytometry analysis of intratumoral CD4+ and CD8+ T cell populations. (h,i) Quantification of DC maturation in dLNs and tumors, respectively . (j) Percentage of tumor-infiltrating CD8+ T cells. Quantitative data are based on n = 3 mice per group. Statistical significance was determined using one-way ANOVA with Tukey’s post hoc test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Conclusion In this study, we report a DNAzyme-enabled nanocatalytic platform, APTZ, that integrates redox modulation with innate immune activation to achieve temporally guided cancer immunotherapy. By coupling Zn2+-triggered DNAzyme cleavage of catalase mRNA with intracellular redox regulation, APTZ induces a coordinated cascade involving ROS amplification, GSHdepletion, mitochondrial dysfunction, mtDNA release, and subsequent activation of the cGAS-STING pathway. This cascade establishes a transient but well-defined intracellular redox sensitization window during which tumor cells exhibit heightened immunogenicity and increased susceptibility to immune intervention. Importantly, this redox sensitization window is not inferred from a single molecular readout, but is supported by the temporal convergence of redox imbalance, mitochondrial stress, and innate immune signaling. Leveraging this intrinsic temporal signature, we demonstrate that synchronization of immune checkpoint blockade with the defined window markedly enhances antitumor efficacy in vivo. The superior therapeutic outcome achieved by the APTZ (5 h) + αPD-1 regimen, compared with out-of-window administration, provides direct evidence that therapeutic timing is a critical determinant of response. Beyond demonstrating a redox-mitochondria-cGAS-STING cascade, this work highlights a conceptual advance over existing STING-activating or ROS-generating nanotherapies. Many current strategies rely on constitutive immune stimulation or sustained oxidative stress, which offer limited guidance for therapeutic scheduling and may compromise immune fitness. In contrast, the DNAzyme cascade in APTZ converts catalytic activity into a temporally confined redox sensitization window, thereby translating intracellular biochemical dynamics into an actionable timing cue. This time-gated design positions APTZ not merely as an immune-activating agent, but as a timing-instructive nanocatalyst that enables rational coordination of redox modulation and immunotherapy. Collectively, our findings establish a generalizable framework in which programmable catalytic cascades are used to define optimal intervention windows for combination cancer therapy. This time-guided strategy may be extendable to other redox-sensitive and immunometabolic pathways, providing new opportunities for precision scheduling and improved efficacy in cancer immunotherapy. Experimental section Preparation of APTZ nanoplatforms DNAzyme-1, DNAzyme-2, and linker strands were mixed at a molar ratio of 1:1:1 in annealing buffer (10 mM Tris-HCl, 50 mM NaCl, pH 8.0) and annealed using a Bio-Rad Thermal Cycler. The AS1411 aptamer was separately annealed by heating to 95 °C for 5 min, followed by controlled cooling to 60 °C. The pre-annealed AS1411 (A) was combined with the PT at a molar ratio of 1:5 (A: PT) in hybridization buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) and incubated at 25 °C for 1-2 h. ZnO NPs were freshly sonicated, added to the APT solution and gently rotated overnight at 4 °C to allow electrostatic and hybridization-driven loading. Following incubation, the APTZ nanoplatform was collected by centrifugation at 12,000 rpm for 10 min and washed three times with PBS to remove unbound DNA. Pellets were resuspended in 1× PBS for subsequent experiments. Zn and DNA content were quantified ICP-MS and UV-Vis spectrophotometry, respectively. Catalytic activity of DNAzyme Zn2+ concentration-dependent cleavage: Substrate DNA and DNAzyme strands were mixed at a 10:1 molar ratio in HEPES buffer (25 mM, pH 7.4, containing 137 mM NaCl) with varying concentrations of ZnCl2 (0, 0.1, 0.5, 1.0, and 2.0 mM). Reactions were carried out at 37 °C for 4 h. Cleavage products were resolved by 20% native PAGE in 1× TBE buffer and visualized under UV light using a gel documentation system.Comparative cleavage efficiency of DNAzyme and mutated DNAzyme (muDNAzyme): Substrate DNA was incubated under identical conditions with either functional DNAzyme or catalytically inactive mutant DNAzyme (muDNAzyme) at ZnCl2 concentrations of 0, 0.1, 0.5, 1.0, and 2.0 mM for 4 h. Reaction mixtures were resolved by 20% native PAGE. Cleavage efficiency was quantified by densitometry of cleaved versus uncleaved bands.pH-responsive cleavage validation: Substrate DNA and APTZ were incubated in HEPES buffer at pH 7.4 (physiological mimic) or pH 5.5 (acidic tumor microenvironment mimic) at 37 °C for 4 h. Cleavage products were analyzed by 20% native PAGE, and gels were imaged to confirm cleavage activity under acidic conditions. Zn2+ concentration-dependent cleavage: Substrate DNA and DNAzyme strands were mixed at a 10:1 molar ratio in HEPES buffer (25 mM, pH 7.4, containing 137 mM NaCl) with varying concentrations of ZnCl2 (0, 0.1, 0.5, 1.0, and 2.0 mM). Reactions were carried out at 37 °C for 4 h. Cleavage products were resolved by 20% native PAGE in 1× TBE buffer and visualized under UV light using a gel documentation system. Zn2+ concentration-dependent cleavage: Substrate DNA and DNAzyme strands were mixed at a 10:1 molar ratio in HEPES buffer (25 mM, pH 7.4, containing 137 mM NaCl) with varying concentrations of ZnCl2 (0, 0.1, 0.5, 1.0, and 2.0 mM). Reactions were carried out at 37 °C for 4 h. Cleavage products were resolved by 20% native PAGE in 1× TBE buffer and visualized under UV light using a gel documentation system. Comparative cleavage efficiency of DNAzyme and mutated DNAzyme (muDNAzyme): Substrate DNA was incubated under identical conditions with either functional DNAzyme or catalytically inactive mutant DNAzyme (muDNAzyme) at ZnCl2 concentrations of 0, 0.1, 0.5, 1.0, and 2.0 mM for 4 h. Reaction mixtures were resolved by 20% native PAGE. Cleavage efficiency was quantified by densitometry of cleaved versus uncleaved bands. Comparative cleavage efficiency of DNAzyme and mutated DNAzyme (muDNAzyme): Substrate DNA was incubated under identical conditions with either functional DNAzyme or catalytically inactive mutant DNAzyme (muDNAzyme) at ZnCl2 concentrations of 0, 0.1, 0.5, 1.0, and 2.0 mM for 4 h. Reaction mixtures were resolved by 20% native PAGE. Cleavage efficiency was quantified by densitometry of cleaved versus uncleaved bands. pH-responsive cleavage validation: Substrate DNA and APTZ were incubated in HEPES buffer at pH 7.4 (physiological mimic) or pH 5.5 (acidic tumor microenvironment mimic) at 37 °C for 4 h. Cleavage products were analyzed by 20% native PAGE, and gels were imaged to confirm cleavage activity under acidic conditions. pH-responsive cleavage validation: Substrate DNA and APTZ were incubated in HEPES buffer at pH 7.4 (physiological mimic) or pH 5.5 (acidic tumor microenvironment mimic) at 37 °C for 4 h. Cleavage products were analyzed by 20% native PAGE, and gels were imaged to confirm cleavage activity under acidic conditions. Lysosomal escape assay After overnight culture, cells were incubated with Cy5-labeled APTZ (final concentration: 200 nM) in complete medium for 1, 2, 4, or 6 h. Following incubation, cells were washed 2-3 times with PBS and stained with LysoTracker Green for 30 min to stain lysosomes. The staining solution was then replaced with fresh culture medium, and live-cell imaging was performed using CLSM to visualize APTZ (red) colocalization with lysosomes (green). For quantitative colocalization analysis, CLSM images were processed using ImageJ software. A linear region of interest (ROI) was drawn across representative cells, and fluorescence intensity profiles for both red and green channels were plotted as a function of distance. The degree of signal overlap was used to assess lysosomal localization versus cytosolic distribution of APTZ at each incubation time point. Intracellular ROS measurement After the indicated treatments, cells were incubated with 10 µM 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA) for 30 min at 37 °C in the dark. Excess probe was removed by washing three times with PBS, and cells were resuspended in fresh medium. For qualitative assessment, intracellular ROS generation was visualized by CLSM via green fluorescence of oxidized DCF. For quantitative analysis, fluorescence intensity was measured using a fluorescence microplate reader (BioTek Synergy H1). Intracellular GSH Level measurement 4T1 cells were seeded in 6-well plates at a density of 5 × 105 cells per well and cultured overnight under standard conditions. After the indicated treatments, cells were lysed, and intracellular total glutathione (GSH) and oxidized glutathione (GSSG) levels were determined using a GSH/GSSG assay kit, according to the manufacturer’s protocol. GSH levels were normalized to total protein content, which was quantified using the BCA protein assay. Cellular oxygen consumption rate analysis Cells were treated with APTZ (final concentration: 600 nM) for varying durations (0, 2, 4, 6, and 8 h). Following treatment, cells were immediately harvested for OCR measurement using an Oroboros O2k high-resolution respirometer (Oroboros Instruments, Austria). For each assay, 1 × 106 cells were resuspended in mitochondrial respiration buffer and allowed to reach a stable baseline oxygen consumption rate. Oligomycin, FCCP, and antimycin A/rotenone (all at 0.1 mM, 5 µL each) were sequentially injected. OCR parameters, including basal respiration, spare respiratory capacity, and coupling efficiency, were determined according to the manufacturer’s instructions. In vivo peritumoral ROS imaging At predetermined time points following APTZ administration, mice received peritumoral injections of 100 µL ROS BriteTM 700 probe (5 µM, prepared in HHBS buffer [Hank’s Balanced Salt Solution with 20 mM HEPES]). Fluorescence signals were acquired immediately after probe administration using the AniView multimodal in vivo imaging system under consistent acquisition settings. Combination therapy with APTZ and PD-1 immune checkpoint blockade Once tumors reached ~ 80 mm3, mice were randomly assigned into six groups (n = 5 per group) for subsequent treatments: (i) Saline (control, i.v.), (ii) PD-1 antibody alone (200 µg per mouse, i.p.), (iii) APTZ alone (36 µM, 100 µL, i.v.), (iv) APTZ followed by PD-1 antibody administered 0.5 h, (v) APTZ followed by PD-1 antibody at 5 h, or (vi) APTZ followed by PD-1 antibody at 8 h. All time intervals (0.5 h, 5 h, and 8 h) refer to fixed post-injection time points calculated from the initial APTZ administration, which was used as a unified temporal reference for all treatment groups. PD-1 antibody was administered every 3 days, while APTZ nanoparticles were injected every 3 days at the indicated dose. Treatments were continued for a total of 14 days. Throughout the treatment period, tumor volumes were measured every two days. Mouse body weights were also recorded every two days to monitor systemic toxicity. In vivo antitumor immune assay At two days after the final treatment, mice were sacrificed and tumor tissues, tumor-draining lymph nodes, and spleens were harvested. Single-cell suspensions were prepared by mechanical dissociation and filtration. For DC maturation analysis, cells were first blocked with anti-CD16/32 to prevent Fc receptor-mediated nonspecific binding, followed by surface staining with the following antibodies: CD45, CD3, CD19, F4/80, CD11c, MHC-II, CD80, and CD86. Zombie Aqua viability dye was included to exclude dead cells. Mature DCs were defined as CD45+CD3-CD19-F4/80-CD11c+MHC-II+CD80+/CD86+ populations. For T-cell profiling, single-cell suspensions from tumors, lymph nodes, and spleens were stained with anti-CD45, anti-CD3, anti-CD4, and anti-CD8a, together with Zombie Aqua viability dye. T-cell subsets were quantified as CD45+CD3+CD4+ (helper T cells) and CD45+CD3+CD8+ (cytotoxic T cells). Samples were acquired on a flow cytometer equipped with 405 nm, 488 nm, and 640 nm lasers. Data analysis was performed using standard compensation controls and gating strategies in FlowJo software. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2